COMMUNIQUÉS West-GlobeNewswire

Inteleos Earns UN ECOSOC Status to Advance Quality Care Worldwide
30/09/2026
Special Consultative Status expands Inteleos’ ability to build health equity through global partners and policy ROCKVILLE, Md., Sept. 30, 2026 (GLOBE NEWSWIRE) -- The United Nations Economic and Social Council (ECOSOC) [...]
Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026
30/09/2026
NESS ZIONA, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced it will [...]
SK pharmteco Announces $200-Plus Million U.S. Investment to Expand Small Molecule and Peptide Capacity
30/09/2026
RANCHO CORDOVA, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced a comprehensive five-year, more than $200 million investment plan to expand and upgrade its U.S. development and manufacturing [...]
ALK expands strategic tablet supply partnership with Catalent
30/09/2026
Inside Information Agreement provides long-term expanded access to Catalent's fast-dissolving (Zydis ® ) tablet formulation technology. Supply robustness secured with prioritised manufacturing capacity increase of ~40% [...]
CJ Biomaterials Secures BPI, TÜV AUSTRIA Certifications for New PHACT™ All-PHA Compound Designed for Home Compostable Cutlery
30/09/2026
PHACT™ CB0104A earned BPI Commercial and Home Compostable, TÜV AUSTRIA OK compost HOME & OK compost INDUSTRIAL Certifications New all-PHA compound is designed for cutlery, caps, enclosures, beauty packaging, and [...]
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development
30/09/2026
- Recently awarded patents have solidified Allarity’s strategy to leverage DRP to ensure the commercial exclusivity of stenoparib TARPON SPRINGS, Fla., September 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the [...]
Hyperion DeFi, Anchorage Digital, and HyperLend Together Announce the First Institutional Credit Facility on Hyperliquid
30/09/2026
Institutional Credit Layer on HyperEVM Secured by Collateral in Qualified Custody at a Federally Chartered Bank DALLAS, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “ [...]
HealthEquity Appoints Moody’s CFO Noémie Heuland to Board of Directors
30/09/2026
DRAPER, Utah, Sept. 30, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the largest independent health savings account (HSA) custodian by account volume and a leader in [...]
Highlight Therapeutics Presents Positive Phase 2b Topline Results of Intralesional BO-112 in Localized Basal Cell Carcinoma as a Late-Breaker at EADV
30/09/2026
Primary composite endpoint met: 61% of patients achieved visual and pathological response across all treated lesions. Complete clinical and pathological response in 56% of high-risk head & neck patients and 62% of [...]
More Than 1,600 Participants Anchor Calroy Health Sciences' Joint Formulation Research
30/09/2026
Three published human studies cover more than 1,600 participants, all testing one complete formulation rather than its separate compounds.*† The earliest study in the set, a prospective trial of 1,236 adults, recorded a [...]
Pharmazz, Inc. Receives U.S. FDA IND Clearance to Initiate Phase 3 Clinical Trial of Sovateltide in Traumatic Brain Injury
30/09/2026
Milestone Validates Proprietary Neural Repair Discovery Engine and Marks Major Expansion of First-in-Class Endothelin-B Receptor Agonist into a Critical Neurotrauma Indication with Significant Unmet Need Sovateltide is [...]
Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
30/09/2026
SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of [...]
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
30/09/2026
Data from BASECAMP expected in Q1 2027 TORONTO, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to [...]
10 Barrel Expands Salty Sips RTD Portfolio with New Blackberry Refresher
30/09/2026
Big Blackberry Flavor Meets Low-Sugar Refreshment in the New Salty Sips Easy-Drinking Vodka Cocktail BEND, Ore., Sept. 30, 2026 (GLOBE NEWSWIRE) -- 10 Barrel Brewing , the Bend-born craft beer brand known for bold beers [...]
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
30/09/2026
– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) – – Rademikibart significantly reduced the rate of new moderate to severe COPD exacerbations [...]
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
30/09/2026
- Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m ² or higher - Topline data now expected in mid-2028 WALTHAM, Mass., Sept. 30, [...]
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
30/09/2026
JADE301 is designed to build on a clinically validated IFN-β mechanism with a differentiated profile designed for infrequent subcutaneous dosing JADE301 demonstrated high-affinity, selective IFN-β binding and greater [...]
OneMedNet Signs Seven Figure Multiyear Agreement to Power a Partner Sold Derivative Data Solution
30/09/2026
First party, direct-from-source Real World Data will feed the Company’s tenth channel partner’s AI models and a licensable derivative dataset that partner will sell MINNEAPOLIS, Sept. 30, 2026 (GLOBE NEWSWIRE) -- [...]
Silo Pharma’s QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility
30/09/2026
Addition of NVIDIA Nemotron models and Hermes runtime expands customer choice across both AI models and agent software SARASOTA, FLA., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the [...]

Pages